Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
Subtype terms (8)
More specific conditions that are subtypes of Glioma in the MeSH hierarchy.
- Astrocytoma
234 drugs (119 approved, 115 experimental)
- Diffuse Intrinsic Pontine Glioma
106 drugs (48 approved, 58 experimental)
- Ependymoma
133 drugs (80 approved, 53 experimental)
- Ganglioglioma
6 drugs (5 approved, 1 experimental)
- Gliosarcoma
174 drugs (90 approved, 84 experimental)
- Medulloblastoma
162 drugs (94 approved, 68 experimental)
- Oligodendroglioma
137 drugs (77 approved, 60 experimental)
- Optic Nerve Glioma
12 drugs (9 approved, 3 experimental)
Drugs by status
Approved for this indication (8)
Phase 4 trials (20)
Phase 3 trials (34)
- fluorodopa
- paclitaxel
- dapagliflozin
- vincristine
- dexamethasone
- vindesine
- vinblastine
- Vorasidenib
- everolimus
- bupropion
- vitamin c
- carboplatin
- bevacizumab
- sulfur hexafluoride lipid-type a microspheres
- antineoplaston AS2-1
- sodium acetate
- copper
- Fluciclovine
- cobimetinib
- selumetinib
- atengenal
- vemurafenib
- chloroquine
- procarbazine
- vorinostat
- lomustine
- tumor-pulsed dendritic cells
- capmatinib
- fcn-159
- cisplatin
- +4 more
Phase 2 trials (251)
- tvi-brain-1
- fludeoxyglucose f-18
- tioguanine
- palonosetron
- indoximod
- sildenafil
- cetuximab
- gd2 car t cells
- magnesium
- oxaliplatin
- aglatimagene besadenovec
- gdc-0084
- dovitinib
- avutometinib
- c5252
- sargramostim
- topotecan
- tetanus toxoid
- act-001
- 131i-tm-601
- ensartinib
- diphtheria toxoid
- il13r alpha peptide
- streptozotocin
- crizotinib
- irinotecan
- i-131-clr1404
- azd-5672
- vismodegib
- 9-ing-41
- +221 more
Phase 1 trials (201)
- ly3214996
- [203pb]vmt-α-net
- abexinostat
- fluorouracil
- primidone
- hydroxyurea
- amg 596
- sgt-53
- ketoconazole
- posaconazole
- cabiralizumab
- pf-06840003
- mycophenolate
- onc206
- vardenafil
- idh1 peptide vaccine
- hsv-1716
- regadensoson
- quercetin
- yyb-103
- carv3-team-e t cells
- autologous cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes
- sulfasalazine
- os2966
- c134
- 13c-pyruvate
- nst-628
- pegylated arginine deiminase
- pf-07799544
- amg 404
- +171 more
Other trials (32)
- 11c acetate
- nkt cells
- 68ga-nota-nfb
- e. coli cd-expressing genetically modified neural stem cells
- rivaroxaban
- bone autograft
- bafetinib
- ga 68-edotreotide
- b7-h3 target, car gene modified gdt cell injection
- il-7
- dexmedetomidine
- genetically-modified neural stem cells expressing e.coli cytosine deaminase
- gx-i7
- 111in-j591
- il-13 rα2 ucar-t cell injection
- midazolam
- NPVAC1
- gadopenteate dimeglumine
- propofol
- 18f dpa-714
- dextrose
- cart-egfrviii t cells
- busulfan
- inactivated influenza vaccine
- somatropin
- 18f-fluoro-dihydroxyphenylalanine
- etanidazole
- bacille calmette-guerin
- lithium
- hla-a2 restricted glioma antigen peptides vaccine
- +2 more
Organizations
Organization Involved with Phase 4 Indications (8)
Organization Involved with Phase 3 Indications (39)
- Kintara Therapeutics, Inc.
- Hannover Clinical Trial Center GmbH
- Northwest Biotherapeutics
- Shandong Lanjin Pharmaceuticals Co.,Ltd
- Agios Pharmaceuticals, Inc.
- Nobel Pharmaceuticals
- Medical Research Council
- Ann & Robert H Lurie Children's Hospital of Chicago
- Maastricht University
- University of Arizona
- Burzynski Research Institute
- Canadian Cancer Trials Group
- Case Western Reserve University
- Eastern Cooperative Oncology Group
- Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
- Northwestern University
- Phoenix Molecular Imaging
- Radiation Therapy Oncology Group
- Sichuan University
- University of Lausanne
- University of Nottingham
- University of Virginia
- Capital Medical University
- Fudan University
- Societe Internationale d'Oncologie Pediatrique (SIOP)
- University of California, Los Angeles
- University of California, San Francisco
- University of Turku
- Tianjin Medical University
- European Organisation for Research and Treatment of Cancer
- +9 more
Organization Involved with Phase 2 Indications (244)
- Pierre Fabre
- Incyte
- AbbVie
- Pinnacle Biologics
- Regeneron
- Daiichi Sankyo
- Eisai
- YM Biosciences
- ProStraken
- Celgene
- Cephalon
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Amgen
- OSI Pharmaceuticals
- Roche
- Candel Therapeutics
- Schering-Plough
- AstraZeneca
- Merck
- Eli Lilly
- Genentech
- MediGene
- MedImmune
- Merck KGaA
- BTG
- Pfizer
- Sanofi
- AEterna Zentaris
- Angiochem Inc
- +214 more
Organization Involved with Phase 1 Indications (88)
- Ambit Biosciences
- Pharmacyclics
- Sigma-Aldrich
- Curis
- Genzyme
- Biogen
- Ariad Pharmaceuticals
- Beijing Pearl Biotechnology Limited Liability Company
- Blaze Bioscience Inc.
- Blue Earth Diagnostics
- Cavion LLC
- DNAtrix, Inc.
- Erimos Pharmaceuticals
- Hebei Senlang Biotechnology Inc., Ltd.
- Merrimack Pharmaceuticals
- Oncolytics Biotech
- Philips
- PTC Therapeutics
- Pharmacia
- Reata Pharmaceuticals, Inc.
- Solvay
- Tocagen Inc.
- Vion Pharmaceuticals
- Apexigen, Inc.
- Tactical Therapeutics, Inc.
- Thallion Pharmaceuticals
- Ziopharm
- Rockefeller University
- Barrow Neurological Institute
- Cancer and Leukemia Group B (CALGB)
- +58 more
Organization Involved with Other Experimental Indications (13)
- Accentia Biopharmaceuticals
- Center Eugene Marquis
- Hoosier Cancer Research Network
- St. Luke's-Roosevelt Hospital Center
- University of Iowa
- University of Toulouse
- University of Montpellier
- Roosevelt Hospital
- Ride for Kids
- BioGene Life Science
- Ellie Kavalieros Fund
- Translational Brain Tumor Research Fund
- Hebei Medical University